Angiogenesis
Angiogenesis inhibitors are compounds that interfere with the formation of new blood vessels, a process critical in cancer growth and metastasis. By inhibiting angiogenesis, these compounds can restrict the blood supply to tumors, slowing or halting their growth. Angiogenesis inhibitors are essential in cancer research and therapeutic development, providing insights into the mechanisms of tumor progression and offering potential treatments for cancer and other angiogenesis-related diseases. At CymitQuimica, we offer a wide range of high-quality angiogenesis inhibitors to support your research in oncology and vascular biology.
Subcategories of "Angiogenesis"
- BTK(166 products)
- Bcr-Abl(118 products)
- EGFR(582 products)
- FAK(72 products)
- FLT(86 products)
- Fibroblast Growth Factor Receptor (FGFR)(180 products)
- JAK(243 products)
- PDGFR(129 products)
- RAAS(89 products)
- Src(82 products)
- Syk(37 products)
- Thrombin(57 products)
- VDA(2 products)
- VEGFR(242 products)
Show 6 more subcategories
Found 2382 products of "Angiogenesis"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
JAK-2/3-IN-1
CAS:JAK-2/3-IN-1 inhibits JAK-2/3 isoforms with sub-250 nM Ki; from US patent US8163732B2.Formula:C20H12ClN3OColor and Shape:SolidMolecular weight:345.79SJ988497
CAS:SJ988497: PROTAC JAK2 degrader, inhibits CRLF2r cell growth, degrades GSPT1, combines Ruxolitinib, linker, Pomalidomide; researched for ALL.Formula:C36H36N10O5Color and Shape:SolidMolecular weight:688.74Multi-kinase-IN-5
Multi-kinase-IN-5 (compound 15c) is a multi-kinase inhibitory agent that shows significant inhibition against a range of protein kinases including RET, KIT,Formula:C19H15N5O2SColor and Shape:SolidMolecular weight:377.42PROTAC BCR-ABL Degrader-1
PROTAC BCR-ABL Degrader-1 (compound PROTAC 1), featuring a 2-oxoethyl linker, promotes Bcr-Abl degradation through the ubiquitin-proteasome pathway andFormula:C43H40N10O6Purity:98%Color and Shape:SolidMolecular weight:792.84Lyso-Monosialoganglioside GM3
CAS:Lyso-Monosialoganglioside GM3 (Lyso-GM3) is an analog of Ganglioside GM3 with antitumor properties. It inhibits the increase in EGFR kinase activity induced by EGF in A431 epithelial cancer cells.Formula:C41H74N2O20Color and Shape:SolidMolecular weight:915.028Ibrutinib-biotin
CAS:Ibrutinib-biotin probe links Ibrutinib to biotin, with IC50 0.755-1.02 nM for BTK (patent WO2014059368A1).Formula:C56H80N12O9SPurity:98%Color and Shape:SolidMolecular weight:1097.39ML228
CAS:ML228 activates HIF pathway and VEGF, with EC50 of 1μM, effective in vitro.Formula:C27H21N5Purity:99.54%Color and Shape:SolidMolecular weight:415.49PROTAC VEGFR-2 degrader-1
CAS:PROTAC VEGFR-2 degrader-1 shows minimal VEGFR-2 inhibition & low anti-proliferative effect on EA.hy926 cells.Formula:C52H61N9O6SColor and Shape:SolidMolecular weight:940.16CG-3-246
CG-3-246 is a dual inhibitor targeting FLT3 and BCL-2, with dissociation constants (Kd) of 63 nM and 4.25 nM, respectively. This compound plays a significant role in acute myeloid leukemia research.Formula:C64H73ClN14O10SColor and Shape:SolidMolecular weight:1265.87VEGFR/PARP-IN-1
VEGFR/PARP-IN-1 (Compound 14b) is a dual inhibitor of VEGFR and PARP with IC50 values of 191 nM and 60.9 nM, respectively.Formula:C29H27N9OPurity:98%Color and Shape:SolidMolecular weight:517.58(R)-3-Hydroxy Midostaurin
CAS:(R)-3-Hydroxy Midostaurin: potent kinase inhibitor, major midostaurin metabolite via CYP3A4, potential AML treatment.Formula:C35H30N4O5Purity:98%Color and Shape:SolidMolecular weight:586.648Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9)
CAS:Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9) is a peptide derived from mouse JAK2, specifically composed of amino acids 475 to 491.Formula:C88H138N20O34P2Purity:98%Color and Shape:SolidMolecular weight:2082.1EGFR/CDK2-IN-2
EGFR/CDK2-IN-2 (compound 6a) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 19.6 nM and 87.9 nM, respectively.Formula:C49H32N12O2S2Purity:98%Color and Shape:SolidMolecular weight:884.99RR-src
CAS:Tyrosine kinase substrate peptideFormula:C64H106N22O21Purity:98%Color and Shape:Lyophilized PowderMolecular weight:1519.66FAK-IN-1
CAS:FAK-IN-1 is a FAK inhibitor with anticancer activities (WO2020231726 (Example 27)).Formula:C24H26F3N7O4SColor and Shape:SolidMolecular weight:565.57DSPE-PEG2000-A7R
DSPE-PEG2000-A7R is a PEG compound consisting of DSPE and a tumor vasculature-targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, a receptor that is overexpressed in various tumors.Color and Shape:Odour SolidMulti-target kinase inhibitor 2
Compound 5K (Multi-target kinase inhibitor 2) is a multi-targeted kinase inhibitor demonstrating activity against EGFR, Her2, VEGFR2, and CDK2 with IC50 valuesPurity:98%Color and Shape:Odour SolidEGFR/CDK2-IN-4
EGFR/CDK2-IN-4 (compound 4c) is a dual inhibitor targeting EGFR and CDK-2, demonstrating IC50 values of 89.6 nM for EGFR and 165.4 nM for CDK-2.Formula:C24H16N6OS2Purity:98%Color and Shape:SolidMolecular weight:468.55EGFR-IN-43
EGFR-IN-43 (17c) is a potent EGFR inhibitor with ER antagonist action, tamoxifen/endoxifen+gefitinib linkage, and strong anticancer activity.Formula:C50H55ClFN5O5Color and Shape:SolidMolecular weight:860.45PROTAC BTK Degrader-1
CAS:Potent, selective oral PROTAC BTK Degrader-1; IC50: 34.51 nM (WT), 64.56 nM (BTK-481S); reduces BTK protein, inhibits tumors.Formula:C43H43N9O4Color and Shape:SolidMolecular weight:749.86
